Enhertu (fam-trastuzumab deruxtecan-nxki) vs Rybrevant (amivantamab-vmjw)
Enhertu (fam-trastuzumab deruxtecan-nxki) vs Rybrevant (amivantamab-vmjw)
Enhertu (fam-trastuzumab deruxtecan-nxki) is a targeted therapy known as an antibody-drug conjugate that combines an anti-HER2 antibody with a chemotherapy drug, specifically designed for the treatment of patients with HER2-positive breast cancer and, more recently, for certain types of HER2-positive gastric cancer. Rybrevant (amivantamab-vmjw), on the other hand, is a bispecific antibody that targets both EGFR and MET receptor pathways and is approved for the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. When deciding between Enhertu and Rybrevant, it is crucial to consider the specific cancer type and molecular profile, as Enhertu is primarily used for HER2-positive cancers, while Rybrevant is tailored for NSCLC with EGFR exon 20 insertion mutations.
Difference between Enhertu and Rybrevant
| Metric | Enhertu (fam-trastuzumab deruxtecan-nxki) | Rybrevant (amivantamab-vmjw) |
|---|---|---|
| Generic name | Fam-trastuzumab deruxtecan-nxki | Amivantamab-vmjw |
| Indications | HER2-positive breast cancer, HER2-mutated non-small cell lung cancer | Non-small cell lung cancer with EGFR exon 20 insertion mutations |
| Mechanism of action | Antibody-drug conjugate targeting HER2 | Bispecific antibody targeting EGFR and MET receptors |
| Brand names | Enhertu | Rybrevant |
| Administrative route | Intravenous | Intravenous |
| Side effects | Nausea, fatigue, vomiting, alopecia, constipation, decreased appetite, anemia, neutropenia, diarrhea, leukopenia, cough, and interstitial lung disease | Infusion-related reactions, rash, paronychia, musculoskeletal pain, dyspnea, nausea, fatigue, edema, stomatitis, vomiting, and decreased appetite |
| Contraindications | Hypersensitivity to fam-trastuzumab deruxtecan-nxki or excipients | Hypersensitivity to amivantamab-vmjw or excipients |
| Drug class | Antibody-drug conjugate | Bispecific antibody |
| Manufacturer | Daiichi Sankyo and AstraZeneca | Janssen Biotech |
Efficacy
Efficacy of Enhertu in Treating Lung Cancer
Enhertu (fam-trastuzumab deruxtecan-nxki) is a targeted therapy that has shown efficacy in the treatment of lung cancer, specifically in patients with HER2-mutant non-small cell lung cancer (NSCLC). In clinical trials, Enhertu has demonstrated significant antitumor activity in this subset of lung cancer patients. The results from a pivotal phase 2 trial showed that Enhertu achieved a remarkable response rate in patients with previously treated HER2-mutant NSCLC, indicating its potential as a promising treatment option for this challenging condition.
The efficacy of Enhertu is particularly notable given the historical difficulty in treating HER2-mutant lung cancers with existing therapies. The response rates observed with Enhertu in clinical studies have been higher than those typically seen with conventional chemotherapy, suggesting that this antibody-drug conjugate could offer a new line of hope for patients with this specific type of lung cancer. Additionally, the duration of response and progression-free survival rates with Enhertu have been encouraging, further supporting its role in the treatment landscape.
Efficacy of Rybrevant in Treating Lung Cancer
Rybrevant (amivantamab-vmjw) is another novel agent that has demonstrated efficacy in the treatment of lung cancer. It is a bispecific antibody that targets both EGFR and MET receptors and has been approved for the treatment of adult patients with NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. Clinical trials have shown that Rybrevant can induce responses in a significant proportion of these patients, which is a notable achievement considering the limited treatment options for this group.
The efficacy data for Rybrevant is based on the results from a multicenter, open-label, single-arm clinical trial, where it exhibited an objective response rate that underscores its potential as a valuable treatment option for patients with EGFR exon 20 insertion-positive NSCLC. The median duration of response has also been promising, indicating that Rybrevant can provide a sustained benefit for patients. These findings represent a significant advancement in the targeted therapy landscape for lung cancer, particularly for those with specific genetic alterations that make their disease difficult to treat.
Regulatory Agency Approvals
Enhertu
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Rybrevant
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Enhertu or Rybrevant today
If Enhertu or Rybrevant are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us